Personalis falls amid a downgrade as competive bid appears unlikely

Tempus Inc. (TEM) expanded its collaboration with Moderna (MRNA) and Merck (MRK) to support the development of a cancer vaccine. Tempus will manage sample collection and provide NGS services. The company also partnered with Bristol Myers Squibb (BMY) to improve clinical trial design. Additionally, Tempus acquired Personalis (PSNL) for $1.5 billion to enhance cancer monitoring. TEM shares were down 1.94% to $70.58 at the time of publication.

Person has agreed to a merger with Tempus, becoming a wholly owned subsidiary. The HSR waiting period expired on Oct 2, 2026. The deal requires stockholder approval and other conditions. Tempus filed relevant documents with the SEC.

Personalis, Inc. (PSNL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on July 20, 2026, Personalis, Inc., a Delaware corporation (“ Personalis ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Tempus AI, Inc., a Nevada corporation (“ Tempus ” or “ Par

Personalis (PSNL) stock fell 2.8% after BTIG downgraded it to Neutral, removing the $16.25 price target. The analyst believes the Tempus AI acquisition will close at the agreed price, with little chance of improvement. BTIG also concluded that the board prioritized deal speed over a higher bid, despite interest from Merck. The S&P 500 and other indices rose, but Personalis' decline was stock-specific.

Tempus AI received FDA clearance for its AI tool, ECG-MR, which detects potential heart valve issues in at-risk patients. This expands the company's AI software offerings into cardiovascular diagnostics. Analysts project revenues of $2.6B and earnings of $18.7M by 2029, assuming 22% yearly revenue growth. The company aims to integrate its data and software tools across various medical fields, including oncology, genetics, and now cardiology.

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.